Financial Review: Guided Therapeutics (OTCMKTS:GTHP) vs. Positron (OTCMKTS:POSC)

Guided Therapeutics (OTCMKTS:GTHP) and Positron (OTCMKTS:POSC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Guided Therapeutics and Positron, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
Positron	0	0	0	0	N/A

Profitability

This table compares Guided Therapeutics and Positron’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-158.84%
Positron	-222.99%	N/A	-65.25%

Earnings & Valuation

This table compares Guided Therapeutics and Positron’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guided Therapeutics	$100,000.00	50.67	-$3.49 million	N/A	N/A
Positron	$740,000.00	43.80	-$1.64 million	N/A	N/A

Positron has higher revenue and earnings than Guided Therapeutics.

Insider & Institutional Ownership

9.7% of Guided Therapeutics shares are owned by institutional investors. 66.8% of Guided Therapeutics shares are owned by company insiders. Comparatively, 17.2% of Positron shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Guided Therapeutics has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Comparatively, Positron has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

About Guided Therapeutics

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.

About Positron

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.